文献速递脊柱关节炎

早期临床应答与依奇珠单抗治疗放射学阳性中轴型脊柱关节炎长期结局相关

Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritis.
PubMed 文献 · RMD Open · 2024-07-14

该研究为COAST-V试验的事后分析,纳入81例未接受过bDMARD的放射学阳性中轴型脊柱关节炎患者,均随机接受依奇珠单抗80 mg每4周一次。第12周或第24周达到ASDAS临床重要改善(CII)者中约70%在第52周达到ASDAS<2.1;两个时间点均未达CII的24例中仅5例(20.8%)第52周达到ASDAS<2.1。结论支持对第12周和/或第24周达到ASDAS CII者继续治疗以提高第52周达到无活动性疾病/低疾病活动的可能性。

要点

  • 第12周达到ASDAS CII的47例中70.2%(33例)第52周达到ASDAS<2.1。
  • 第24周达到ASDAS CII的52例中71.2%(37例)第52周达到ASDAS<2.1。
  • 第12周和第24周均未达CII的24例中仅20.8%(5例)第52周达到ASDAS<2.1。

核心结论

  • 该分析强化了当前推荐,即对第12周和/或第24周达到ASDAS CII者继续治疗可提高第52周获得无活动性疾病/低疾病活动的可能性。

研究设计与样本

  • COAST-V(NCT02696785)为3期试验,纳入未接受过bDMARD的放射学阳性中轴型脊柱关节炎患者,随机接受依奇珠单抗80 mg每4周一次。
  • 本分析为事后分析,纳入81例随机分配至依奇珠单抗80 mg每4周一次的患者。
  • 缺失数据按无应答处理。

主要发现

  • 81例中47例(58.0%)第12周达到ASDAS CII,其中70.2%(33例)第52周达到ASDAS<2.1。
  • 81例中52例(64.2%)第24周达到ASDAS CII,其中71.2%(37例)第52周达到ASDAS<2.1。
  • 第12周和第24周均未达到ASDAS CII的24例中,5例(20.8%)第52周达到ASDAS<2.1。

关键数值与推荐

  • ASDAS CII定义为ΔASDAS≥1.1。
  • 治疗目标为无活动性疾病(ASDAS<1.3)或至少低疾病活动(1.3≤ASDAS<2.1)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Assessment of SpondyloArthritis international Society-European Alliance of Associations for Rheumatology recommendations for axial spondyloarthritis (axSpA) management include patient assessment for biological disease-modifying antirheumatic drug (bDMARD) treatment response after at least 12 weeks of treatment. The current treat-to-target strategy for axSpA is to achieve inactive disease (ID; Axial Spondyloarthritis Disease Activity Score (ASDAS) <1.3) or at least low disease activity (LDA; 1.3≤ASDAS<2.1).To investigate the association between treatment response at week 12 and/or week 24 and attainment of the ASDAS<2.1 treat-to-target recommendation at week 52 in bDMARD-naïve patients with radiographic (r-)axSpA treated with ixekizumab (IXE). METHODS: This post hoc analysis included patients randomly assigned to IXE 80 mg every 4 weeks from COAST-V (NCT02696785), a phase 3 trial in bDMARD-naïve patients with r-axSpA. The proportion of patients who achieved ASDAS<2.1 at week 52 was measured among those who attained or not clinically important improvement (CII, ∆ASDAS≥1.1) response, and among those with ID, LDA and high or very high disease activity at week 12 and/or week 24. Non-response was assumed for missing data. RESULTS: Amongst 81 patients, 47 (58.0%) achieved ASDAS CII at week 12, with 70.2% (n=33) achieving ASDAS<2.1 at week 52. At week 24, 52 (64.2%) patients achieved ASDAS CII, with 71.2% (n=37) achieving ASDAS<2.1 at week 52. Of the 24 patients who did not achieve ASDAS CII at either week 12 or week 24, 5 (20.8%) achieved ASDAS<2.1 at week 52. CONCLUSION: This analysis reinforces the current recommendation that continuing treatment in those achieving ASDAS CII at week 12 and/or week 24 increases the likelihood of obtaining ID/LDA at week 52. TRIAL REGISTRATION NUMBER: NCT02696785.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Ramiro S, Lukas C, Bessette L, et al. Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritis. RMD Open. 2024. PMID: 39004432. doi:10.1136/rmdopen-2024-004429

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。